Revance Therapeutics, Inc. (RVNC)vsVertex Pharmaceuticals Inc (VRTX)
RVNC
Revance Therapeutics, Inc.
$3.65
0.00%
HEALTHCARE · Cap: $381.02M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 4571% more annual revenue ($12.00B vs $256.94M). VRTX leads profitability with a 32.9% profit margin vs -71.8%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
RVNC
Avoid32
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for RVNC.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -21.0% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : RVNC
Revenue growth of 10.7% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : RVNC
The primary concerns for RVNC are EPS Growth, Market Cap, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
RVNC profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
RVNC carries more volatility with a beta of 0.95 — expect wider price swings.
RVNC is growing revenue faster at 10.7% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 32/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Revance Therapeutics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?